167 related articles for article (PubMed ID: 23037726)
1. [Treatment strategy for childhood acute lymphoblastic leukemia].
Horibe K
Rinsho Ketsueki; 2012 Oct; 53(10):1538-48. PubMed ID: 23037726
[No Abstract] [Full Text] [Related]
2. Eliminating a gold standard in childhood acute lymphoblastic leukemia?
Raetz EA; Carroll WL
Pediatr Blood Cancer; 2006 Sep; 47(3):242-4. PubMed ID: 16421903
[No Abstract] [Full Text] [Related]
3. [Treatment strategy for adult acute lymphoblastic leukemia].
Takeuchi J
Rinsho Ketsueki; 2012 Oct; 53(10):1528-37. PubMed ID: 23037725
[No Abstract] [Full Text] [Related]
4. [Acute lymphoblastic leukemia in the adult].
Gökbuget N
Dtsch Med Wochenschr; 2011 Dec; 136(48):2466-9. PubMed ID: 22109577
[No Abstract] [Full Text] [Related]
5. Cooperative study group for childhood acute lymphoblastic leukaemia (COALL): long-term results of trials 82,85,89,92 and 97.
Escherich G; Horstmann MA; Zimmermann M; Janka-Schaub GE;
Leukemia; 2010 Feb; 24(2):298-308. PubMed ID: 20016530
[TBL] [Abstract][Full Text] [Related]
6. Late relapse of childhood acute lymphoblastic leukemia and pcr-monitoring of minimal residual disease: how much time can elapse between "molecular" and clinical relapse?
Aricò M; Germano G; del Giudice L; Ziino O; Locatelli F; Basso G
Haematologica; 2002 Apr; 87(4):ELT19. PubMed ID: 11940504
[No Abstract] [Full Text] [Related]
7. Application of a chemiluminescent methodology for detection of minimal residual disease in childhood acute lymphoblastic leukemia.
Lo Nigro L; Poli A; Mirabile E; Costantino F; Schilirò G
Haematologica; 2001 Dec; 86(12):1314-6. PubMed ID: 11726326
[No Abstract] [Full Text] [Related]
8. Integrating molecular information into treatment of childhood acute lymphoblastic leukemia--a perspective from the BFM Study Group.
Stanulla M; Cario G; Meissner B; Schrauder A; Möricke A; Riehm H; Schrappe M
Blood Cells Mol Dis; 2007; 39(2):160-3. PubMed ID: 17532236
[TBL] [Abstract][Full Text] [Related]
9. Wilms' tumor gene 1 (WT1) expression in childhood acute lymphoblastic leukemia: a wide range of WT1 expression levels, its impact on prognosis and minimal residual disease monitoring.
Boublikova L; Kalinova M; Ryan J; Quinn F; O'Marcaigh A; Smith O; Browne P; Stary J; McCann SR; Trka J; Lawler M
Leukemia; 2006 Feb; 20(2):254-63. PubMed ID: 16341043
[TBL] [Abstract][Full Text] [Related]
10. Level of minimal residual disease prior to haematopoietic stem cell transplantation predicts prognosis in paediatric patients with acute lymphoblastic leukaemia: a report of the Pre-BMT MRD Study Group.
Krejci O; van der Velden VH; Bader P; Kreyenberg H; Goulden N; Hancock J; Schilham MW; Lankester A; Révész T; Klingebiel T; van Dongen JJ
Bone Marrow Transplant; 2003 Oct; 32(8):849-51. PubMed ID: 14520434
[No Abstract] [Full Text] [Related]
11. Prognostic value of MRD-dynamics in childhood acute lymphoblastic leukemia treated according to the MB-2002/2008 protocols.
Meleshko AN; Savva NN; Fedasenka UU; Romancova AS; Krasko OV; Eckert C; von Stackelberg A; Aleinikova OV
Leuk Res; 2011 Oct; 35(10):1312-20. PubMed ID: 21596436
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer--Childhood Leukemia Cooperative Group.
Cavé H; van der Werff ten Bosch J; Suciu S; Guidal C; Waterkeyn C; Otten J; Bakkus M; Thielemans K; Grandchamp B; Vilmer E
N Engl J Med; 1998 Aug; 339(9):591-8. PubMed ID: 9718378
[TBL] [Abstract][Full Text] [Related]
13. Minimal residual disease-guided treatment deintensification for children with acute lymphoblastic leukemia: results from the Malaysia-Singapore acute lymphoblastic leukemia 2003 study.
Yeoh AE; Ariffin H; Chai EL; Kwok CS; Chan YH; Ponnudurai K; Campana D; Tan PL; Chan MY; Kham SK; Chong LA; Tan AM; Lin HP; Quah TC
J Clin Oncol; 2012 Jul; 30(19):2384-92. PubMed ID: 22614971
[TBL] [Abstract][Full Text] [Related]
14. Investigation of minimal residual disease in childhood and adult acute lymphoblastic leukaemia by molecular analysis.
Foroni L; Harrison CJ; Hoffbrand AV; Potter MN
Br J Haematol; 1999 Apr; 105(1):7-24. PubMed ID: 10366253
[No Abstract] [Full Text] [Related]
15. [The protocol of minimal residual disease in childhood acute lymphoblastic leukemia].
Zhang RD; Liu Y; Gong WY
Zhonghua Er Ke Za Zhi; 2011 Aug; 49(8):596-8. PubMed ID: 22093422
[No Abstract] [Full Text] [Related]
16. Impact of pretransplant minimal residual disease after cord blood transplantation for childhood acute lymphoblastic leukemia in remission: an Eurocord, PDWP-EBMT analysis.
Ruggeri A; Michel G; Dalle JH; Caniglia M; Locatelli F; Campos A; de Heredia CD; Mohty M; Hurtado JM; Bierings M; Bittencourt H; Mauad M; Purtill D; Cunha R; Kabbara N; Gluckman E; Labopin M; Peters C; Rocha V
Leukemia; 2012 Dec; 26(12):2455-61. PubMed ID: 22555150
[TBL] [Abstract][Full Text] [Related]
17. Long-term results of treatment of childhood acute lymphoblastic leukemia in the Czech Republic.
Stary J; Jabali Y; Trka J; Hrusak O; Gajdos P; Hrstkova H; Sterba J; Blazek B; Hak J; Prochazkova D; Cerna Z; Smisek P; Sedlacek P; Vavra V; Mihal V; Hrodek O;
Leukemia; 2010 Feb; 24(2):425-8. PubMed ID: 20016535
[No Abstract] [Full Text] [Related]
18. [Guidelines for the diagnosis and treatment of childhood acute lymphoblastic leukemia].
; ; ;
Zhonghua Er Ke Za Zhi; 2014 Sep; 52(9):641-4. PubMed ID: 25476423
[No Abstract] [Full Text] [Related]
19. Minimal residual disease in childhood acute lymphoblastic leukemia: current status and challenges.
Izraeli S; Waldman D
Acta Haematol; 2004; 112(1-2):34-9. PubMed ID: 15179003
[TBL] [Abstract][Full Text] [Related]
20. [Understanding the guidelines for the diagnosis and treatment of childhood acute lymphoblastic leukemia].
Wu M; Li Z
Zhonghua Er Ke Za Zhi; 2014 Sep; 52(9):645-8. PubMed ID: 25476424
[No Abstract] [Full Text] [Related]
[Next] [New Search]
